 Currently, the CGCI has elucidated some previously undetermined genetic alterations in medulloblastoma and B-cell non-Hodgkin lymphoma.The next steps for the CGCI is to identify genomic alternations in HIV+ tumors and in Burkitt's Lymphoma.Some high-throughput sequencing techniques that are used by the CGCI include